Table of Contents Table of Contents
Previous Page  298 / 812 Next Page
Information
Show Menu
Previous Page 298 / 812 Next Page
Page Background

S294

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

EW513

Problems in long-term treatment

with atypical antipsychotics:

hyperprolactinemia

C. Franch

1 ,

, G. Medina

2

, M.D. Ortega

3

, M.E. Calzada

1

,

V. Molina

2

1

Complejo Asistencial Universitario de León, Psiquiatría, Leon, Spain

2

Hospital Clínico Universitario de Valladolid, Psiquiatría, Valladolid,

Spain

3

Centro de Salud Mental Cartagena, Psiquiatría, Murcia, Spain

Corresponding author.

Introduction

Schizophrenia and other psychotic disorders are

associated with high rates of morbidity and mortality, caused by

the use of specific treatments as well as health factors directly

related to those processes. One of the high-frequency side effects

in patients treated with classic and atypical antipsychotics is

hyperprolactinemia. It causes alterations in neuroendocrine sphere

(amenorrhea, galactorrhea, gynecomastia

. . .

), and other mid- and

long-term effects (osteoporosis, cardiovascular risk increase and

increased risk of developing cancers - specifically in breasts and

endometrium).

Objectives

Check hyperprolactinemia induction by maintained

treatment with atypical antipsychotics.

Methodology

A naturalistic prospective study was conducted fol-

lowing 75 patients onmaintenance treatmentwith a single atypical

antipsychotic during 24 months. Anthropometric and laboratory

datawere collected, alongwith the presence of different endocrine-

metabolic during the 2-year study alterations.

Results

Changes in prolactin levels were found in a large num-

ber of patients, with statistically significant differences between

0 (basal) and 24 months (Basal [M= 26.27; SD = 21], 2 years

[M= 38.08, SD = 34.65];

t

=

2.758;

P

= 0.013], with hyperpro-

lactinemia increasing from 46.6% of patients at baseline to 65.5%

at 2 years, mainly with paliperidone and risperidone long acting

injection (statistically significant increase in both cases)

( Fig. 1 ).

Conclusions

Paliperidone and risperidone long acting injectable

induce increased prolactin levels in patients in long-term antipsy-

chotic treatment.

Fig. 1

Prolactine variation at 24 months.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.631

EW514

Cortical and subcortical morphology

deficits in cerebral gray matter in

patients with schizophrenia and not

affected siblings

F. Pastoriza

1 ,

, L. Galindo

2

, A. Mané

3

, D. Bergé

3

, N. Pujol

3

,

M. Picado

4

, A. Bulbena

2

, O. Vilarroya

2

, V. Pérez

5

1

IMIM - Universitat Autònoma de Barcelona, USM l’Hospitalet Nord-

ICS, Barcelona, Spain

2

Institut de Neuropsiquiatria i Addiccions - Parc de Salut Mar- IMIM-

Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain

3

Institut de Neuropsiquiatria i Addiccions- Parc de Salut Mar- IMIM,

Psychiatry, Barcelona, Spain

4

IMIM, Neuroimaging, Barcelona, Spain

5

Institut de Neuropsiquiatria i Addiccions- Parc de Salut Mar- IMIM-

Universitat Autònoma de Barcelona, Psychiatry- CIBERSAM G21,

Barcelona, Spain

Corresponding author.

Objective

Explore the basis of cortical morphometry in patients

with schizophrenia and non-affected siblings by Magnetic Reso-

nance Structural analyzing cortical thickness.

Methods

Twenty-nine patients with schizophrenia treated with

atypical antipsychotics and clinically stable in the last 6 months

were recruited. Twenty-three not affected siblings of patients with

schizophrenia and 37 healthy volunteers were recruited. Magnetic

Resonance Structural was performed. FreeSurfer the brain imag-

ing software package for analysis of Cortical Thickness is used. In

the analysis of group differences in cortical thickness (CT) with the

general linear model (GLM), the

P

-value was established in 0003

following the Bonferroni correction to control for multiple com-

parisons (seven regions of interest a priori in each hemisphere).

Results

Significant differences in cortical thickness between

patients and healthy controls. Differences between groups were

calculated by general linear model (GLM) with age and sex as cov-

airables

( Table 1 ).

Conclusions

In applying the correction for multiple comparisons,

differences in bilateral-lateral orbitofrontal, medial orbitofrontal-

right and left temporal transverse frontal cortex are significant. Our

study replicates previous findings and provides further evidence of

abnormalities in the cerebral cortex, particularly in the frontal and

temporal regions, being characteristic of schizophrenia.

Table 1

Significant differences in cortical thickness in healthy con-

trols, not affected siblings and patients with schizophrenia.

P: patients; S: siblings; C: controls.